Received Aug 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | UNK | Y1A212M | OT |
inappropriate use due to the administration of ipol instead of the intended ppd with no adverse event; ipol administered intradermally with no reported adverse event; Initial information received on 18-Aug-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 16 years old female patient who was inappropriately administered to IPV (Vero) [IPOL] instead of the intended ppd and was administered intradermally with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 18-Aug-2025, the patient received 0.1mL (frequency once) of suspect IPV (Vero) (lot Y1A212M, expiry date 31-Jan-2027, strength standard) via intradermal route in unknown administration site for Immunization and inappropriately administered to Ipol instead of the intended ppd with no adverse event (wrong product administered) and also administered intradermally with no reported adverse event (incorrect route of product administration) (latency same day). Reportedly, the administration had taken place within 30 minutes of the call and requested information on any adverse reactions to look for in the patient after this administration. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.